Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb organized the 2022 C2C4C cycling event, involving over 350 employees from 23 countries who raised more than $2 million for cancer research. The journey covered nearly 7,000 miles through various global locations. Participants, including survivor Blanca Bedoya, emphasized the event's mission beyond cycling, linking personal growth with a commitment to patients. Since its inception in 2014, C2C4C has raised around $14 million for cancer initiatives worldwide. The 10th anniversary is scheduled for next year, emphasizing ongoing support for the cancer community.
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 41st Annual Healthcare Conference on January 9, 2023. The presentation will be led by Giovanni Caforio, M.D., the Board Chair and CEO, at 7:30 a.m. PST / 10:30 a.m. EST. A live webcast will be available at http://investor.bms.com, with additional materials accessible at the start of the event. A replay will follow. Bristol Myers Squibb is dedicated to developing innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE: BMY) has finalized the sale of its manufacturing facility in location value="LU/us.ny.syracu"Syracuse, New York to LOTTE BIOLOGICS. This divestiture aims to optimize its manufacturing network and support its product portfolio. As part of the deal, LOTTE BIOLOGICS will offer employment to all Syracuse site employees and will handle manufacturing for Bristol Myers Squibb at the same facility under a new contract manufacturing organization relationship.
Bristol Myers Squibb (NYSE:BMY) will reveal its Q4 2022 financial results on February 2, 2023, during a 9:00 a.m. ET conference call. Investors can listen via a live webcast or by dialing 888-300-3045 (U.S. toll-free) or +1 646-568-1027 (international) with conference code: 3734085. Replay options will be available post-call, accessible until February 16, 2023. For more details about the company, visit BMS.com.
Bristol Myers Squibb (NYSE: BMY) presented new data from its multiple myeloma portfolio at the 64th ASH Annual Meeting. The results include advancements in bispecific T cell engagers and CAR T therapies, such as alnuctamab, Abecma, and GPRC5D CAR T. Notable findings include alnuctamab showing reduced toxicity with sustained tumor response, while Abecma demonstrated high overall response rates in patients after relapse. The company emphasizes its commitment to innovative treatments in addressing the complex challenges of multiple myeloma.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.57 per share, payable on February 1, 2023, to stockholders on record by January 6, 2023. This marks a 5.6% increase from last year’s dividend of $0.54 and continues a strong trend, being the 14th consecutive year of increases and the 91st year of dividend payments overall, which reflects the company's commitment to returning value to its shareholders. An additional dividend of $0.50 per share will be paid on preferred stock on March 1, 2023.
On Nov. 29, 2022, Bristol Myers Squibb (NYSE: BMY) announced a multi-year research collaboration with Envisagenics to leverage the latter's SpliceCore® AI platform for oncology therapeutic development. The partnership aims to enhance BMY's oncology pipeline by identifying alternative splicing-derived targets. Envisagenics will receive upfront and milestone payments tied to development progress. The SpliceCore platform promises rapid drug target identification through advanced RNA-sequencing data analysis, potentially transforming modern drug development.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Wolfe Research Healthcare Conference on November 16, 2022, at 3:20 p.m. ET in location value="LU/us.ny.nyc"New York City. Chris Boerner, Executive Vice President and Chief Commercialization Officer, will address questions during the session. Investors and the public can listen via a live webcast at investor.bms.com, with an archived version available later that day.
Bristol Myers Squibb (NYSE: BMY) recently presented significant findings from its cardiovascular portfolio at the AHA Scientific Sessions 2022. Key topics included a featured presentation on CAMZYOS® (mavacamten) for obstructive hypertrophic cardiomyopathy, showcasing long-term efficacy and safety data from various studies. Highlights also included analyses of racial disparities in anticoagulant treatment among Medicare beneficiaries and pooled safety data from multiple trials. These presentations underscore the commitment to innovative cardiovascular treatments aimed at improving patient outcomes.
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 COMMANDS trial of Reblozyl (luspatercept-aamt) achieved primary and key secondary endpoints, demonstrating significant improvement in red blood cell transfusion independence and hemoglobin levels for patients with very low, low, or intermediate-risk myelodysplastic syndromes (MDS) requiring transfusions. The safety profile remains consistent with previous studies. Detailed findings will be presented at an upcoming medical meeting as the company collaborates with health authorities for further evaluations.